{"name":"SynAct Pharma Aps","slug":"synact-pharma-aps","ticker":"","exchange":"","domain":"","description":"SynAct Pharma Aps is a biotechnology company focused on developing innovative treatments for inflammatory and autoimmune diseases. The company's lead candidate, AP1189, is in Phase 2 clinical trials for multiple indications. SynAct Pharma aims to address significant unmet medical needs with its pipeline of potential therapies.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AP1189","genericName":"AP1189","slug":"ap1189","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AP1189","genericName":"AP1189","slug":"ap1189","phase":"phase_2","mechanism":"AP1189 is a glucagon receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOdEhIV3lPamJHbFNhMmFsZTJHXzRMTGtHZUs0dV9lRTVQV0VDQmUwVEdDc0hReDZzcDVmLS1ONTRZa2dYWWR6R0V0dW9kd0xkQl9Da3d4T3lDZU9nSFNYTi1KV1MzWTc4WFpPbFJzby0zdDVMenV0dnZoejZDaXZxcGo5LTBpUFFQRVlRMEZXRlBtOENVV1ppSmlZTmYwQldsQUZSSzJWeWFrcW5oeUp3ZkZmanlzZmxKVWlVSWV2WElpNGV3THNfM0xDaW1yM3oteFFEdDVtREVZaElvZE9LR0JhaTkzTi1sVnpCc1hlaW5seXZ1V1FFRW4tQVRMN1NUbzVqU3doYlJjNG1MUm5EaDJ3TDJtLTNqWmNuNzBWZXVMUE16Nzl5STBCWQ?oc=5","date":"2026-04-06","type":"pipeline","source":"GlobeNewswire","summary":"Idiopathic Membranous Nephropathy Market is Predicted to - GlobeNewswire","headline":"Idiopathic Membranous Nephropathy Market is Predicted to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQMmJSaWczeXVCWmpmdWlxOGZIWjhlRnhmSmV3ZXNEZDduNGxhQWs0T1dOYm8tSWdvZWRjX093RlhPczBvZWFUVXo2bVY2bjlNTlY2a3BIcE1oVWhoMnp4bXZjT3JpVzV5cTZfbmoxcWktcmtta3RJaENteXY5UVF3THBtN29BNXl5bkhQemhwc3p5UjNHUi1NSEU2aEJCeEMySjR0TWNfdDA5V2c2U00yNkszbkJmdmNHajlEcXFReW9HSWU2bFA1S1Vn?oc=5","date":"2026-03-31","type":"pipeline","source":"TradingView","summary":"Change in number of shares and voting rights in Synact Pharma AB - TradingView","headline":"Change in number of shares and voting rights in Synact Pharma AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFB0RjFLcjVoOElYbFc0ejJKY0VTYjFKc0ZnSmhHTEQ0clpJOWFHZ0tDLWduVmhEZXktR1VLdXpHYm9FMnFSaW14ZnRlVzBjR3ZiVVJzUzU0OERqUF9raVHSAWNBVV95cUxOZDV6ZEFsdXM3UGhzNmZKSHN2TDFnQ3BxXzZ2WlBXUzRfd2hSVTd5TmthazVIdHU3clBiWTRjT3pYR3BIUk9mMXYwaXJQaTZONUd0X05JWlBmVHhTRHIwZFlyaFk?oc=5","date":"2026-03-26","type":"trial","source":"Bitget","summary":"SynAct Pharma Dengue Study: Strategic Opportunity or Diversion Before RA Turning Point? - Bitget","headline":"SynAct Pharma Dengue Study: Strategic Opportunity or Diversion Before RA Turning Point?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxONXkwdkpRb1dwaWpXVklxcVZOem9TZXFzeGt6emVMSWlrOXZWR2FFdjk0Tmt6Vl9RSUdJRXItWFNwVnBlLUtRLUNLMXVrblhBaWRPSzA3N0tYOVpkWXhibWNHbjEzclJaNXVDRVA3RnRIOGVneDhIN1FLUmJHQ2lYX240QWJpS25uWEktNnc1TjFMaF8zNDlEYjJPSHBwT1U?oc=5","date":"2026-03-17","type":"pipeline","source":"openPR.com","summary":"Nephrotic Syndrome Treatment Pipeline Shows Strong Momentum as 3+ Pharma Companies in the Race | DelveInsight - openPR.com","headline":"Nephrotic Syndrome Treatment Pipeline Shows Strong Momentum as 3+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOclFnU1Y4ZnIyRlFFMzMybU1PV2MxRmpDbUxFR3ZKY1VqX0M1NWxhZzB2R1dHNUMzOVpTV2VKMHdFNDdybG9XcHNpdlluZEh0dmhKU0Vvd0JpUTkwYUc4X3czc1NuN1E1cTgyX2dZYjdLOWRKTWVKaThsc2RYNVFYcjVWcjRMU2d4bHBCc1FoUWxqVzhxX3JHMjJ3Z3dnNkVIS1MwdzJoUndETVVmMVdfYVd0UVdrWW5wNExZNWpZTGM1aHVRU2hvekk3RnNPeGZreVdwNzdXMUVzVEU2QzRHWTN6Y3JDWkZs?oc=5","date":"2026-03-02","type":"pipeline","source":"TradingView","summary":"SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK - TradingView","headline":"SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQa2NUcmpHWDRoUkhLMGVGUXZKYVcwUldMSmxOVDYxTndvS1lDT3lnNlVwcVIwT1d1T2lvQ2h0MnducGc2emdRTGpVa2tROW1QY1lWZ0oydThvUDJoN19JSzN0a293SEdLOHRzb3VvTzZpd3cyMkJMNlFCNDFHU1pQVEJR?oc=5","date":"2024-03-22","type":"pipeline","source":"Biostock","summary":"SynAct's new CEO : \"I'm hitting the ground running\" - Biostock","headline":"SynAct's new CEO : \"I'm hitting the ground running\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBMZHVpUFdMSTFfa3hhd3BsVXNTMFhxQTEwN2pBWXZramdpTmp4RWpGdlk4bU01UkVNMWRTaUx5N0d6T1NMR2ZzOWxQOVZHSDhKRWV6U0E0TDRxT2tCWFFJ?oc=5","date":"2022-07-20","type":"pipeline","source":"TradingView","summary":"SYNACT Stock Price and Chart — OMXSTO:SYNACT - TradingView","headline":"SYNACT Stock Price and Chart — OMXSTO:SYNACT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBoZXBZb1F4ci1WVjBMNERMZWYxNFFiZldUZDZrX1JhRlh2c094YkVKc2UtYlY1YnhJQ0JYcmRGNmhDMDltRzRaQ2xYdUpOSW9xVFhVM0FrTkgxWmJmNmtRVHhaUnhGTDc2Z1hsMXJVdw?oc=5","date":"2021-08-03","type":"pipeline","source":"medwatch.com","summary":"Anders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: \"It's going to be more DIY-based\" - medwatch.com","headline":"Anders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: \"It's going to be more DIY-ba","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}